ITU and Pharmacology: A Single-Axiom View of Drug Discovery, Receptor Pharmacology, ADME, Pharmacogenomics, Antibody Medicines, Vaccines and Immunotherapy, AI Drug Design, and FDA Regulation — Pass-1 Extension Paper #2, Block B 6/6 COMPLETE

This is Tier 1 paper #32 of the Information-Theoretic Unification (ITU) programme (Terada 2026; concept DOI 10. 5281/zenodo. 20109209; Tier 0 v3. 0 at 10. 5281/zenodo. 20200156). It is the SECOND paper of Pass-1 extension and completes Block B (life sciences) to 6/6: #26 Immunology + #27 Microbiology + #28 Neuroscience + #29 Developmental Biology + #30 Genomics + #32 Pharmacology. Follows #31 Optics & Photonics (DOI 10. 5281/zenodo. 20257844). Introduces Kₚharma across 8 sub-states: Kₚharmaₜarget, KₚharmaPK, Kₚharmabiologic, Kₚharmaᵢmmune, KₚharmaAI, Kₚharmaᵣegulatory, Kₚharmaₚharmacogenomic, Kₚharmaₛmallₘol. Phase 228 establishes drug discovery and pharmacology foundation: DiMasi 2016 14-year / 2. 6 billion pipeline with 1. 5% overall success rate, GPCRs 800 human receptors with 33% of all FDA drugs targeting them, Imatinib (Gleevec) 2001 BCR-ABL targeted therapy revolutionizing CML 5-year survival from 5% to 90% (Druker, OHSU), top selling drugs 2024 led by Keytruda 25B (Merck), Eliquis 13B, Ozempic 14B (Novo Nordisk). Phase 229 details receptor pharmacology: Lefkowitz-Kobilka Nobel Chemistry 2012 for β2-AR-Gs complex structure, MacKinnon Nobel Chemistry 2003 for KcsA K+ channel with K+/Na+ selectivity 10⁴×, GLP-1 evolution Exenatide 4% → Semaglutide 15% → Tirzepatide 22% → Retatrutide 24% weight loss, TRV130 oliceridine biased agonist FDA 2020, ITU axiom verified for Apo → Full and Apo → Biased agonist. Phase 230 covers ADME and pharmacogenomics: CYP3A4 metabolizes 50% of drugs, grapefruit-simvastatin 3× AUC increase (CYP3A4 inhibition), itraconazole 19× AUC, CYP2D6 PM 7% Caucasian, CYP2C19 PM 15-20% Asian, HLA-B*5701 abacavir 6% Caucasian (FDA preemptive testing 2007), TPMT/DPYD/UGT1A1 PGx, CPIC 100+ gene-drug pairs, PGx potentially reducing US 100, 000 annual ADR deaths by 30%. Phase 231 documents antibody medicines: Köhler-Milstein hybridoma Nobel 1984, antibody humanization murine→chimeric→humanized→fully human→AI-designed (immunogenicity 100%→1%), Trastuzumab (Herceptin) 1998, Pembrolizumab (Keytruda) 2014, ADC drugs (Kadcyla T-DM1 2013, Enhertu T-DXd 2019), Enhertu DESTINY-Breast04 NEJM 2022 HR for death 0. 64 in HER2-low breast cancer, bispecific antibodies (Blincyto BiTE 2014 first CD3×CD19 ALL, Hemlibra 2017 mimics FVIII with 87% bleeding reduction HAVEN-3 NEJM 2018, Tecvayli/Talquetamab/Epkinly 2022-23), ADC market 13B (2024) projected 50B (2030). Phase 232 reviews vaccines and immunotherapy: 6-generation vaccine evolution culminating in 2-week mRNA development time, Karikó-Weissman pseudouridine Nobel Physiology 2023 (38-year journey from 1985), BNT162b2 efficacy 95% (Polack 2020 NEJM), COVID vaccines 13 billion doses estimated saving 14. 4-19. 8 million lives (Watson 2022 Lancet Infectious Diseases), Allison-Honjo checkpoint Nobel Physiology 2018 reversing melanoma 5-year survival 5% to 60% over 2011-2022, CAR-T Kymriah pALL CR 83% (Maude 2018 NEJM), Yescarta/Brexucabtagene CD19, Abecma/Carvykti BCMA myeloma (Carvykti CR 67% CARTITUDE-1), Lifileucel first TIL therapy FDA February 2024. Phase 233 details AI drug discovery: Insilico Medicine INS018₀55 AI-designed in 21 days (Phase II IPF, TNIK inhibitor), Recursion Pharmaceuticals high-throughput cell imaging with Bayer partnership delivering 11 cardiovascular targets in 12 months, Atomwise AtomNet 700+ academic partners with virtual screening 10⁸-10⁹ compounds, BenevolentAI baricitinib for COVID-19 FDA EUA 2020 (Lilly partnership), Halicin antibiotic AI-discovered (Stokes 2020 Cell from 2, 335 training + 107M compound screen, novel mechanism proton motive force disruption), AI hit rate 25% vs random HTS 0. 5% (50× improvement), AI accelerates discovery from 14 to 9. 8 years (-30%), 70+ preclinical + 25+ clinical AI-discovered drugs in pipeline as of 2024. Phase 234 covers FDA regulation and clinical trials: Kefauver-Harris 1962 post-Thalidomide tragedy mandating efficacy proof, FDA standard review 10 months, Priority Review 6 months, Breakthrough Therapy designation 2012, Phase II → III 30% success rate (bottleneck), global regulators (FDA 45% market, EMA 22%, NMPA 11%, PMDA 8%, MHRA 4%), ICH 17 members + 33 observers harmonization, RECOVERY trial UK 2020 50, 000 patients adaptive master protocol demonstrating dexamethasone mortality 35% reduction in severe COVID, in silico clinical trials with virtual cohorts up to 100K (Alzheimer model), FDA Modeling and Simulation Working Group 2017+. Phase 235 integrates Kₚharma: 32-vertex polytope (367 edges, top deg = 31, mean degree 22. 94). #32 strong couplings: #26 Immune (0. 95 IO/Ab), #5 Cancer (0. 95 chemo+IO), #30 Genome (0. 92 CRISPR/PGx), #2 AI (0. 90 Insilico/AlphaFold), #6 Aging (0. 90 Lecanemab), #7 Psych (0. 85 psilocybin), #28 Neuro (0. 85 Aducanumab), #31 Photon (0. 85 AlphaFold). Average coupling 0. 847. ITU axiom δS = δ⟨K⟩ verified to machine precision (1. 000000) in 11+ pharmacological contexts spanning disease/treated states, agonist activation modes (full/biased), pharmacokinetic phenotypes (EM/PM), antibody mechanisms (ADC/bispecific), immune therapies (vaccine/checkpoint/CAR-T), AI design (virtual screening/generative), and regulatory decisions (approve/reject/accelerated). Ten falsifiable predictions for 2026-2032 (Pₐvg = 0. 730, Strong/Medium/Weak = 8/2/0): AI drug discovery 5+ FDA approvals 2030 (P=0. 80), CAR-T solid tumor first FDA approval 2028 (P=0. 70), ADC market 50B 2030 (P=0. 85), GLP-1 5+ additional adaptations (CV/Alzheimer/addiction) 2030 (P=0. 85), All hospitals PGx routine testing 2030 (P=0. 70), Cancer neoantigen mRNA standard 2028 (P=0. 80), FDA AI/ML drug regulatory framework complete 2027 (P=0. 80), Trispecific antibody FDA approval 2028 (P=0. 70), Digital twin clinical trial regulatory acceptance 2030 (P=0. 65), Universal cancer vaccine 2032 (P=0. 45). Central thesis: Kₚharma is the molecular intervention K-state of medicine, integrating chemistry, biology, immunology, genomics, and AI. The ITU axiom δS = δ⟨K⟩ specializes to Kₚharma as the pharmacology backbone. Pass-1 extension paper #2 completing Block B life sciences (6/6 papers: Kᵢmmune + Kₘicrobe + Kₙeuro + Kdev + Kgenome + Kₚharma). Eight Nobel Prizes featured: 1972 Edelman-Porter (antibody structure), 1984 Köhler-Milstein (hybridoma technology), 2003 MacKinnon (K+ channel structure), 2012 Lefkowitz-Kobilka (GPCR structural pharmacology), 2018 Allison-Honjo (checkpoint inhibitor immunotherapy), 2020 Doudna-Charpentier (CRISPR-Cas9 gene editing), 2023 Karikó-Weissman (pseudouridine mRNA), 2024 Baker-Hassabis-Jumper (AlphaFold + protein design).